{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 15 of 81', 'PH', 'Pulmonary Hypertension', 'PID', 'Patient identification number', 'PK', 'Pharmacokinetic(s)', 'PKS', 'Pharmacokinetics analysis set', 'Plc', 'Placebo', 'PLS', 'Physical limitation score', 'PPS', 'Per protocol analysis set', 'PR', 'PR interval', '(e)PRO', '(Electronic) patient reported outcome', 'PTT', 'Partial thromboplastin time', 'QC', 'Quality control', 'QoL', 'Quality of Life', 'QRSD', 'QRS duration', 'QT', 'QT interval', 'QTc', 'QT interval corrected for HR', 'QTcB', 'Formula of Bazett', 'QTcF', 'Formula of Fridericia', 'RAVE', 'Electronic data capture system used by the sponsor', 'RBC', 'Red blood cells', 'RDW', 'Red cell distribution width', 'SAE', 'Serious adverse event', 'SAF', 'Safety analysis set', 'SAP', 'Statistical analysis plan', 'SBP', 'Systolic blood pressure', 'SD', 'Standard deviation', 'SFS', 'Symptom frequency score', 'sGC', 'Soluble guanylate cyclase', 'STEMI', 'ST-elevation myocardial infarction', 'SUSAR', 'Suspected Unexpected Serious Adverse Reaction', 'SVR', 'Systemic vascular resistance', 'TIA', 'Transient ischemic attack', 'TSS', 'Total symptom score', 'US', 'United States of America', 'VAS', 'Visual analogue scale', 'VO2', 'Oxygen uptake', 'WBC', 'White blood cells']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 16 of 81', '3.', 'Introduction', '3.1', 'Background', 'Heart failure is a leading cause of CV morbidity and mortality, and constitutes a major public', 'health problem worldwide. Patients suffering from HFpEF are a large and growing', 'population; the relative proportion of HFpEF has increased to more than 50% of all HF', 'hospitalizations (1). Predisposing conditions for HFpEF are advanced age, female gender,', 'diabetes, obesity, arterial hypertension, and LV hypertrophy. While mortality in outpatient', 'cohorts appears to be lower for HFpEF than HFrEF, hospitalizations for HFpEF have', 'increased over time. HFpEF patients also have substantially reduced functional capacity and', 'quality of life (2), and they need a therapy that addresses these limitations. However, no', 'specific therapy has been approved to reduce cardiovascular risk or to improve functional', 'status in patients with HFpEF, and recommendations have thus far been limited to', 'symptomatic treatment of congestive symptoms by diuretics, and to treating causes and', 'comorbidities including hypertension, coronary artery disease, and atrial fibrillation (3). US', 'guidelines were recently updated with a new class IIb recommendation stating that', 'aldosterone receptor antagonists might be considered to decrease hospitalizations in', 'appropriately selected patients with HFpEF (with EF 45%, elevated BNP levels or HF', 'admission within 1 year, estimated glomerular filtration rate >30 mL/min, creatinine <2.5', 'mg/dL, potassium <5.0 mEq/L) (4). ESC guidelines on HF also provide no evidence level A', 'recommendations for the treatment of patients with HFpEF and reiterate that no treatment has', 'yet been shown, convincingly, to reduce morbidity or mortality in patients with HFpEF (5).', 'Trials that established the clinical benefits of ACE inhibitors, angiotensin receptor antagonists', 'and \u00df-blockers beyond their use in arterial hypertension, CAD or for rate control have all', 'selected patients on the basis of their reduced EF. Subsequent trials in patients with HFpEF', 'did not confirm equal effectiveness in this patient group (6). Since patients with HFpEF are', 'highly symptomatic with a poor quality of life, it is important to find new therapies that can', 'alleviate symptoms and improve patient well-being (5). Therefore, there is need for new drug', 'targets such as cGMP. The nitric oxide-soluble guanylate cyclase-cGMP signaling pathway is', 'a relevant mechanism in HF that remains unaffected by neurohumoral antagonists. cGMP', 'deficiency causes two important pathophysiologies in HF:', '1.', 'Myocardial dysfunction including impaired relaxation, diastolic stiffening and', 'myocardial energy wastage. cGMP is a powerful antihypertrophic mediator in the', 'heart (7). It is specifically reduced in myocardial biopsies of patients with HFpEF,', 'and bypassing the cGMP deficiency by in vitro protein kinase G administration', 'corrects inappropriately high resting tension forces of human cardiomyocytes (8).', 'In a genetic sGC knockout model sGCa1 mice (deficiency in the al subunit', 'results in decreased enzymatic sGC activity, whereas the total sGC knockout is not', 'viable) increased cardiac contractility, arterial elastance and impaired ventricular', 'relaxation were observed (9).', '2.', 'Endothelial dysfunction, i.e. disturbed endothelium-dependent vasotone regulation', 'due to a reduced NO bioavailability, including the myocardial microcirculation.', 'Endothelial dysfunction contributes to the pathophysiology of HFpEF (10).', 'Previous attempts to increase cGMP remain limited. The long-term effects of nitrates and', 'exogenous NO donors are limited by tolerance (11), and they also cause endothelial', 'dysfunction, oxidative stress, and release of endothelin-1 (12). The venoselectivity of these']\n\n###\n\n", "completion": "END"}